10 · Policy & regulatory watch

Policy & regulatory watch

Erasca says 44% of 25 responded; it’s Phase 1 · No. 052 · · About 2 min read

Bookmarks need a Mind Club sign-in. How sign-in works

An RNAi approval, no CMS prices yet with ten days to the deadline, and drugmakers’ pledges on trial sites in China.

AgencyActionDetail
FDA (11.18; announced 11.19)ApprovalLivsayis (cemdisiran), Regeneron, for adults with acetylcholine receptor antibody positive generalized myasthenia gravis, per Alnylam; FDA’s novel approvals list dates the action 11.18
CMSNegotiated prices for 2028Not yet published as of 11.20; the CMS page, last modified 11.02, still says negotiations are under way (call 10)
White House (11.18)FDA commissionerWithdrew Heidi Overton’s nomination, first reported 11.17; Kyle Diamantas remains acting commissioner, as reported
House Select Committee on ChinaTrial sitesMerck, Lilly, AbbVie, Pfizer and BMS said they will not open new trial sites in Xinjiang or at sites tied to China’s military, as reported; existing sites are not covered
FDA (11.19)FilingHumacyte submitted a supplemental BLA for its acellular tissue engineered vessel in dialysis access

CMS negotiated prices page (opens another website in a new tab) Gov; Alnylam, via Yahoo Finance (11.19) (opens another website in a new tab); Humacyte, via BioSpace (11.19) (opens another website in a new tab) Co; FDA Novel Drug Approvals 2026 (opens another website in a new tab) Gov; Healio (11.18) (opens another website in a new tab); Fierce Healthcare (opens another website in a new tab); STAT (11.19) (opens another website in a new tab) Press. We found no CRL, advisory committee, clinical hold or guidance dated in the window.

RED TEAM

We rely on a company release for the Livsayis approval; FDA’s list confirms the 11.18 date; we did not read the label. The trial-site pledges cover new sites only, so how much changes in practice is unclear. Analysis